Skip to main content

Zhonghong Medical Reports H1 2026 Net Profit Surge of Over 26-Fold

Written by Customer Service on . Posted in Public Companies.

Zhonghong Pulin Medical Products Co., Ltd.

XIAMEN, China, Sept. 21, 2026 (GLOBE NEWSWIRE) — Zhonghong Pulin Medical Products Co., Ltd. (“Zhonghong Medical”, 300981.SZ) recently disclosed its interim report for 2026. According to the report, the company achieved a revenue of RMB 1.478 billion in the first half of the year, representing a year-on-year growth of 19.46%. Net profit attributable to shareholders of the listed company reached RMB 159 million, marking a dramatic year-on-year surge of 2,662.38%. Net profit excluding non-recurring gains and losses totaled RMB 115 million, registering a year-on-year increase of 974.79%.

The interim report highlights that revenue from the health protection products segment reached RMB 1.352 billion in H1, with a gross margin of 23.68% – an increase of 14.70 percentage points year-on-year. The strong financial performance was primarily driven by two key factors: first, rising selling prices for health protective gloves, which led to a notable expansion in gross margin; second, the company’s continuous efforts in operational optimizations such as efficiency enhancements in raw material cyclical management, improved management on production and inventory, production line upgrades, and product portfolio optimization. These measures significantly improved cost containment, enhanced operational efficiency, and drove substantial year-on-year gains in profitability and net margins.

Regarding global production footprint, the construction of Phase I of Zhonghong Medical’s Indonesian manufacturing base is progressing steadily. Once completed, the facility is expected to add an annual production capacity of 8 billion to 10 billion nitrile gloves.

Zhonghong Medical currently operates four primary business divisions: Health Protection, Safe Infusion, Innovation Incubation, and International Business Development. Among these, the Health Protection division serves as the company’s business cornerstone and primary revenue driver. As a leading domestic manufacturer of medical examination and surgical gloves, Zhonghong Medical remains the sole producer in China with large-scale manufacturing capabilities for polyisoprene (PI) surgical gloves.

According to the interim report, the company has established a comprehensive R&D network pillared by five research institutes in Tangshan (Hebei Province), Shanghai, Yichun (Jiangxi Province), Shenzhen (Guangdong Province), and Guilin (Guangxi Zhuang Autonomous Region), alongside its Hainan subsidiary. The system spans product development in new-function gloves, innovative material gloves, high-end surgical consumables, and veterinary care. Zhonghong Medical has successfully developed advanced offerings including PI gloves, double-layer indicator gloves, microsurgical gloves, antiviral gloves, radiation-shielding gloves, and veterinary temperature sensors, further strengthening its product competitive edge in the market.

CONTACT: Contact person: Ms. Pan, Tel: 86-10-63074558

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.